Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Rational Analyst -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (1520)	11/12/1998 12:12:00 PM
From: HeyRainier	Read Replies (2) \| Respond to of 1720

Stocks that are still surviving the above filter, and continue to maintain recovery and potential continued outperformance status for the January Effect: WTEC, YELL, TDFX, PRIA, NSPK, FLH, ESST, DGTC, ALNK. DUSA made it; RT

To: HeyRainier who wrote (1520)	11/12/1998 9:57:00 PM
From: HeyRainier	Read Replies (1) \| Respond to of 1720

Love those chart scans. Some big gainers since being posted on Friday night's list: ESST: +62.7% PRIA: +32.2% DUSA: +27.7% EQNX: +13.8% Waiting for SOC and NSPK. Maybe. RT

To: HeyRainier who wrote (1520)	11/30/1998 9:44:00 AM
From: Scott H. Davis	Respond to of 1720

[Tardy response to Rainier] From your reversal list, I have TTP (was TTNP until it moved from baby NAZ to AMEX) Its a developmental stage biotech with good prospects. Kind of unusual in that they don't have a large R&D/technology platform of their own. They are currently in the mode of acquiring rights to therapies and taking them thru clinical trials, rather than doing the pre-clinical work themselves (much less overhead but more difficult to assess) Current lead product is Iloperidone for the treatment of schizophrenia, which is in Phase III where the expenses of the trial are entirely underwritten by Novartis (nice deal). They have three therapeutic vaccines in phase II cancer trials. Good preliminary results good efficacy with great safty. I really like the therapeutic vaccine approach (no surprise since VICL is my favorite biotech & I'm starting to look at ONXX too). Uses the Immune system to target the cancer rather than the older cytotoxic approach where you hoped you killed more of the cancer cells than healthy cells and hoped the patient could stomach the side effects. Also potentially promissing as a combinational therapy. Pivanexis also Phase II for the treatment of refractory stage III and IV non-small cell lung cancer. Finally, they have a promissing Parkinsons therapy (either late pre-clinical or at IND stage) Richard H likes the basic concept of the cancer vaccines but is skeptical since a lot of people have tried a similar approach (anti-idiotype sp?) and ultimately failed. He likes the Iloperidone prospects. Hope this helps. Scott